Hot Medical Stocks To Invest In Right Now

Cyndi Takacs went the extra miles last year to earn additional paid time off, and she plans to do the same this year.

She and other employees at Excelas, a medical consulting firm with 44 staffers in Cleveland, get one extra hour of paid time off for every 33,000 steps they take during the first three months of the year, for up to three extra days of paid leave.

To meet the goal last year, she did laps around the parking lot at lunch, and she took the dogs out for an extra walk at night. "Earning time off with pay is a great motivator to get me moving," says Takacs, the company's office coordinator. Excelas also makes charitable donations based on the employees' walking milestones.

The walking program is part of the company's wellness initiative, which also includes nutrition and stress-reduction programs. "The immediate objective is to improve the health of the staff," says Jean Bourgeois, the company's president and founder. "If our programs lead to a reduction in our health care costs over time, as we believe they will, that's the end game that benefits our company as a whole."

Top 10 Electric Utility Companies To Own In Right Now: Neuroderm Ltd (NDRM)

Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.

ND0612L for moderate Parkinson�� disease

ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.

The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.

The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.

ND0612H for severe Parkinson�� disease

The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.

ND0680 for severe Parkinson�� disease

ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680

ND0701 for severe Parkinson�� disease

ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.

ND0801 for Cognitive Disorders

ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.

The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.

Advisors' Opinion:

• [By Johanna Bennett]

  NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.

Hot Medical Stocks To Invest In Right Now: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

• [By Bryan Murphy]

  If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.

Hot Medical Stocks To Invest In Right Now: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:

• [By James E. Brumley]

  Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.

• [By Jake L'Ecuyer]

  Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.

Hot Medical Stocks To Invest In Right Now: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By Tim Brugger]

  After confirming an unsolicited takeover bid from privately held investment firm Royalty Pharma in late February, Ireland-based Elan (NYSE: ELN  ) announced today that its board has unanimously rejected the offer.

Hot Medical Stocks To Invest In Right Now: Cerner Corp (CERN)

Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT) solutions, services, devices and hardware. Cerner solutions optimize processes for healthcare organizations. These solutions are licensed by approximately 9,300 facilities globally, including more than 2,650 hospitals; 3,750 physician practices 40,000 physicians; 500 ambulatory facilities, such as laboratories, ambulatory centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 40 employer sites and 1,600 retail pharmacies. The Company operates in two segments: domestic and global. The domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The global segment includes revenue contributions and expenditures linked to business activity in Argentina, Aruba, Australia, Austria, Canada, Cayman Islands, Chile, China (Hong Kong), Egypt, England, France, Germany, Guam, India, Ireland, Italy, Japan, Malaysia, Morocco, Puerto Rico, Qatar, Saudi Arabia, Singapore, Spain, Sweden, Switzerland and the United Arab Emirates. On May 23, 2011, the Company acquired Resource Systems, Inc. On October 17, 2011, the Company acquired Clairvia, Inc. Effective March 18, 2013, it acquired Labotix Automation Inc.

The Company designs and develops software solutions on the unified Cerner Millennium architecture, a person-centric computing framework, which combines clinical, financial and management information systems. This architecture allows providers to access an individual�� electronic health record (EHR) at the point of care, and it organizes and proactively delivers information to meet the specific needs of physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals and consumers. It also offers a range of services, including implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, healthcare data analysis, clinical proc! ess optimization, transaction processing, employer health centers, employee wellness programs and third party administrator (TPA) services for employer-based health plans.

The Company offers a longitudinal, person-centric EHR, which gives clinicians electronic access to the right information at the right time and place to achieve optimal health outcomes. Medical information and care regimens accessible from home enables consumers to manage their conditions and adhere to treatment plans, creating a medium between physicians and individuals. Its Cerner ITWorks is a suite of services, which creates an alignment between Cerner and its clients. Its Cerner RevWorks includes solutions and services to help healthcare organizations improve their revenue cycle functions. It offers clinic, pharmacy and wellness services directly to employers.

The Company's Healthe Intent Chart Search includes clinical meanings of words located within the electronic medical record (EMR), as well as the context in which those words occur to create algorithms that identify and rank information contextually. The Healthe Intent platform also provides the ability to apply algorithms against contextual clinical activity to recommend clinical action.

The Company competes with Allscripts Healthcare Solutions, Inc., Computer Programs and Systems, Inc. (CPSI), Epic Systems Corporation, GE Healthcare Technologies, Healthcare Management Systems, Inc. (HMS), Healthland, Inc., Computer Sciences Corporation (iSoft), Keane, Inc., McKesson Corporation, Medical Information Technology, Inc. (Meditech), Siemens Medical Solutions Health Services Corporation, Quadramed Corporation, Accenture plc, Affiliated Computer Services (ACS), Cap Gemini S. A., Computer Task Group, Inc. (CTGHS), Dell, Inc., Deloitte Consulting LLP, Hewlett-Packard Company, IBM Corporation, maxIT Healthcare LLC, AmazingCharts.com, Inc., Athenahealth, Inc., eClinicalWorks LLC, e-MDs, Inc., Greenway Medical Technologies, MED3000, Inc., Quality Sy! stems, In! c., Conceptual MindWorks, Inc., Vitera Healthcare Solutions, API Healthcare, CapsuleTech, Inc., CareFusion Corporation, GE Healthcare Technologies, iSirona, LLC, McKesson Corporation, Omnicell, Inc., Accretive Health, Inc., Capario, Inc., Emdeon Corporation, McKesson Corporation, MedAssets, Inc., Optum, Inc., SSI Group, Inc. and 3M Company.

Advisors' Opinion:

• [By Lu Wang]

  Cerner (CERN) Corp. rallied 8 percent, the most in the S&P 500, to a record $52.61. The provider of electronic medical records said it reached a multiyear agreement to provide services to Intermountain Healthcare.

• [By Keith Speights]

  Cerner (NASDAQ: CERN  ) stands out as another big beneficiary of the government's helpful hands. In March 2009, the big EHR vendor reported revenue of $1.67 billion. By the end of last year, Cerner's revenue had jumped to over $2.66 billion.

• [By James E. Brumley]

  Truth be told, it's not clear if SK3 Group Inc. (OTCMKTS:SKTO) is best described when compared to a name like Cerner Corporation (NASDAQ:CERN), or to a Gentiva Health Services, Inc. (NASDAQ:GTIV). The company's got elements of both major industries being represented by CERN and GTIV (home health care, and information technology), with the addition of another budding industry thrown into the mix. One thing IS clear though... SKTO shares have decidedly reversed a nasty downtrend, and may now be one of the market's best small cap healthcare speculative trades.

• [By Susan J. Aluise]

  Another positive: Florida’s Agency for Health Care Administration chose MGLN to administer its Medicaid specialty plan for individuals with serious mental illness. The program will be implemented in eight regions throughout Florida and in 40 of its 67 counties. Right now, MGLN stock has a forward P/E of about 19 — roughly average for healthcare stocks.

  Healthcare Stocks: Cerner (CERN)

  When it comes to achieving success with the Affordable Care Act, don’t underestimate the power of information technology to help or hinder the progress. Given the disastrous technical problems that attended last fall’s launch, the heat is on all parties to ensure that the technology works as advertised.

Hot Medical Stocks To Invest In Right Now: SearchCore Inc (SRER)

SearchCore, Inc., formerly General Cannabis, Inc., incorporated in 2003, is a technology service provider. As of December 31, 2011, the Company was engaged in the medicinal cannabis industry. The Company assists the physicians, dispensaries, and end-users within the medicinal cannabis industry in finding each other and in advertising their businesses. All of its operations are conducted through its wholly owned subsidiaries. On January 5, 2012, WeedMaps, LLC (WeedMaps) acquired substantially all the assets of MMJMenu, LLC. On October 31, 2011, General Merchant Solutions, Inc. discontinued all retail credit card processing operations. On January 11, 2011, the Company acquired all the assets of Revyv, LLC. On December 31, 2012, the Company acquired Sports Asylum, Inc. In February 2013, it acquired ModularHomes.com.

WeedMaps Media, Inc. is its wholly owned subsidiary, and its primary operation is the Internet Website, www.weedmaps.com. WeedMaps.com is an online finder site service that allows patients to find local medical cannabis dispensaries, which are also referred to as collectives. Dispensaries are locations where patients who have received letters of recommendation from a healthcare provider can purchase medicinal cannabis, as well as a variety of other non-cannabis related items including, but not limited to, apparel accessories, posters, bumper stickers, concert tickets, books and musical compact disc�� (CD��).

General Marketing Solutions, Inc. is its wholly owned subsidiary, and its primary operation is the Internet Website, www.cannabiscenters.com. General Management Solutions, Inc. is its wholly owned subsidiary that oversees and provides all of the human resources issues for employees, including hiring, terminating and employee benefits. The Company has two additional wholly owned subsidiaries; General Processing Corporation, CannaCenters Corporation (CannaCenters), and two subsidiaries, namely LV Luxuries Incorporated (which operated as makeup.com) and General ! Health Solutions, Inc. (CannaCenters.com).

Advisors' Opinion:

• [By Peter Graham]

  Small cap communications or Internet stocks American Community Development Group Inc (OTCMKTS: ACYD), Globalstar, Inc (OTCMKTS: GSAT) and SearchCore Inc (OTCMKTS: SRER) have been rather quiet lately for investors after making some noise back in September. Nevertheless, all three are still getting some mentions in various investment newsletters or alerts and not because they are the subject of paid promotions. So are these small cap stocks about to make some noise? Here is a closer look: